Mirapex 1mg Tablets Recall: Low Weight Tablets Risk
Boehringer Ingelheim recalls Mirapex 1mg tablets due to low weight detected in stability testing. Affected lots may have inconsistent dosing.
Lower-risk recall
Failed Tablet/Capsule Specifications: identification of low weight tablets during routine stability testing.
Contact the company
What happened, in plain English
Boehringer Ingelheim is recalling Mirapex 1mg tablets because some tablets were found to be too light during quality checks. This could mean the medication dose is inconsistent, which might affect treatment effectiveness. Read more at govinfonow.com/recall/39120-mirapex-1mg-tablets-recall-low-weight-tablets-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/39120-mirapex-1mg-tablets-recall-low-weight-tablets-risk · Updated October 5, 2026 · FDA enforcement record: FDA #D-0991-2019
Cite this page
“Mirapex 1mg Tablets Recall: Low Weight Tablets Risk.” GovInfoNow, updated October 5, 2026. https://govinfonow.com/recall/39120-mirapex-1mg-tablets-recall-low-weight-tablets-risk. Based on FDA recall #D-0991-2019 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0991-2019%22&limit=1).
Why it’s dangerous
During routine quality testing, some tablets were identified as having lower weight than expected. This could lead to inconsistent medication dosing, potentially affecting treatment outcomes for conditions like Parkinson's disease.
Who’s affected
Prescription users of Mirapex 1mg tablets with lot number AA3280A (expired September 2019) are affected. Patients on this medication for movement disorders are most at risk.
How to tell if you have this one
Check for Mirapex 1mg tablets in a folding carton with lot number AA3280A, manufactured in Germany, and expired by September 2019. The product is prescription-only and distributed by Boehringer Ingelheim.
- Brand
Boehringer Ingelheim- Category
Drug
What to do — step by step
Check Product Details
Verify the lot number on the packaging; affected units have lot AA3280A.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 6 months after the firm started it.
- Firm started the recall
- FDA classified it Class III
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0991-2019 (March 7, 2019) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0991-2019 to see it in context.
- Plain-language summary written by qwen3:4b on October 5, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.